{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:48Z","timestamp":1786980288330,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA026582"],"award-info":[{"award-number":["R01 CA026582"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01 CA124787"],"award-info":[{"award-number":["P01 CA124787"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["K12 CA088084"],"award-info":[{"award-number":["K12 CA088084"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The University of Texas MD Anderson Cancer Center","award":["Institutional Research Grant"],"award-info":[{"award-number":["Institutional Research Grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00520-019-04791-4","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T07:03:07Z","timestamp":1556521387000},"page":"261-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial"],"prefix":"10.1007","volume":"28","author":[{"given":"G. Brandon","family":"Gunn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito R.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Garden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Shelley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton D.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab Y.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"4791_CR1","doi-asserted-by":"publisher","unstructured":"Garden AS, Kies MS, Morrison WH, Weber RS, Frank SJ, Glisson BS, Gunn GB, Beadle BM, Ang KK, Rosenthal DI, Sturgis EM (2013) Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol 8(21). \nhttps:\/\/doi.org\/10.1186\/1748-717X-8-21","DOI":"10.1186\/1748-717X-8-21"},{"issue":"13","key":"4791_CR2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/cncr.28672","volume":"120","author":"DI Rosenthal","year":"2014","unstructured":"Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, Lu C, Garden AS, Morrison WH, Cleeland CS, Gunn GB (2014) Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module. Cancer 120(13):1975\u20131984. \nhttps:\/\/doi.org\/10.1002\/cncr.28672","journal-title":"Cancer"},{"issue":"11","key":"4791_CR3","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/hed.24879","volume":"39","author":"RP Goepfert","year":"2017","unstructured":"Goepfert RP, Fuller CD, Gunn GB, Hanna EY, Lewin JS, Zaveri JS, Hubbard RM, Barrow MP, Hutcheson KA (2017) Symptom burden as a driver of decisional regret in long-term oropharyngeal carcinoma survivors. Head Neck 39(11):2151\u20132158. \nhttps:\/\/doi.org\/10.1002\/hed.24879","journal-title":"Head Neck"},{"key":"4791_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ctro.2017.10.005","volume":"8","author":"H Mirghani","year":"2018","unstructured":"Mirghani H, Blanchard P (2018) Treatment de-escalation for HPV-driven oropharyngeal cancer: where do we stand? Clin Transl Radiat Oncol 8:4\u201311. \nhttps:\/\/doi.org\/10.1016\/j.ctro.2017.10.005","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"4791_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbi.2006.09.006","volume":"21","author":"R Dantzer","year":"2007","unstructured":"Dantzer R, Kelley KW (2007) Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 21(2):153\u2013160. \nhttps:\/\/doi.org\/10.1016\/j.bbi.2006.09.006","journal-title":"Brain Behav Immun"},{"issue":"7","key":"4791_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/nrclinonc.2012.88","volume":"9","author":"R Dantzer","year":"2012","unstructured":"Dantzer R, Meagher MW, Cleeland CS (2012) Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol 9(7):414\u2013426. \nhttps:\/\/doi.org\/10.1038\/nrclinonc.2012.88","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"4791_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bph.12139","volume":"169","author":"N Garrido-Mesa","year":"2013","unstructured":"Garrido-Mesa N, Zarzuelo A, Galvez J (2013) Minocycline: far beyond an antibiotic. Br J Pharmacol 169(2):337\u2013352. \nhttps:\/\/doi.org\/10.1111\/bph.12139","journal-title":"Br J Pharmacol"},{"issue":"5","key":"4791_CR8","doi-asserted-by":"publisher","first-page":"R168","DOI":"10.1186\/ar3491","volume":"13","author":"CJ Smith","year":"2011","unstructured":"Smith CJ, Sayles H, Mikuls TR, Michaud K (2011) Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects. Arthritis Res Ther 13(5):R168. \nhttps:\/\/doi.org\/10.1186\/ar3491","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"4791_CR9","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1002\/1529-0131(200110)44:10<2235::AID-ART385>3.0.CO;2-A","volume":"44","author":"JR O\u2019Dell","year":"2001","unstructured":"O\u2019Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF (2001) Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 44(10):2235\u20132241","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4791_CR10","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1523\/JNEUROSCI.21-08-02580.2001","volume":"21","author":"T Tikka","year":"2001","unstructured":"Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J (2001) Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 21(8):2580\u20132588","journal-title":"J Neurosci"},{"issue":"12","key":"4791_CR11","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1001\/archneurol.2010.191","volume":"67","author":"JM Plane","year":"2010","unstructured":"Plane JM, Shen Y, Pleasure DE, Deng W (2010) Prospects for minocycline neuroprotection. Arch Neurol 67(12):1442\u20131448. \nhttps:\/\/doi.org\/10.1001\/archneurol.2010.191","journal-title":"Arch Neurol"},{"issue":"5","key":"4791_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1515\/revneuro-2013-0040","volume":"24","author":"C Li","year":"2013","unstructured":"Li C, Yuan K, Schluesener H (2013) Impact of minocycline on neurodegenerative diseases in rodents: a meta-analysis. Rev Neurosci 24(5):553\u2013562. \nhttps:\/\/doi.org\/10.1515\/revneuro-2013-0040","journal-title":"Rev Neurosci"},{"issue":"6","key":"4791_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00004850-200411000-00004","volume":"19","author":"RM Bonelli","year":"2004","unstructured":"Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP (2004) Neuroprotection in Huntington\u2019s disease: a 2-year study on minocycline. Int Clin Psychopharmacol 19(6):337\u2013342","journal-title":"Int Clin Psychopharmacol"},{"issue":"Suppl 1","key":"4791_CR14","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.4103\/0976-500X.120966","volume":"4","author":"C Leporini","year":"2013","unstructured":"Leporini C, Saullo F, Filippelli G, Sorrentino A, Lucia M, Perri G, Gattuta GL, Infusino S, Toscano R, Dima G, Olivito V, Paletta L, Bottoni U, De Sarro G (2013) Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: a case review. J Pharmacol Pharmacother 4(Suppl 1):S78\u2013S85. \nhttps:\/\/doi.org\/10.4103\/0976-500X.120966","journal-title":"J Pharmacol Pharmacother"},{"issue":"8","key":"4791_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1200\/JCO.2015.62.3918","volume":"34","author":"B Melosky","year":"2016","unstructured":"Melosky B, Anderson H, Burkes RL, Chu Q, Hao D, Ho V, Ho C, Lam W, Lee CW, Leighl NB, Murray N, Sun S, Winston R, Laskin JJ (2016) Pan Canadian Rash Trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer. J Clin Oncol 34(8):810\u2013815. \nhttps:\/\/doi.org\/10.1200\/JCO.2015.62.3918","journal-title":"J Clin Oncol"},{"issue":"Pt 4","key":"4791_CR16","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/aws072","volume":"135","author":"S Casha","year":"2012","unstructured":"Casha S, Zygun D, McGowan MD, Bains I, Yong VW, Hurlbert RJ (2012) Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain 135(Pt 4):1224\u20131236. \nhttps:\/\/doi.org\/10.1093\/brain\/aws072","journal-title":"Brain"},{"issue":"10","key":"4791_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/hed.20602","volume":"29","author":"DI Rosenthal","year":"2007","unstructured":"Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, Weber RS, Lewin JS, Garden AS, Ang KK, X SW, Cleeland CS (2007) Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck 29(10):923\u2013931. \nhttps:\/\/doi.org\/10.1002\/hed.20602","journal-title":"Head Neck"},{"issue":"7","key":"4791_CR18","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/cncr.29154","volume":"121","author":"Q Shi","year":"2015","unstructured":"Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS (2015) Racial\/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121(7):1138\u20131146. \nhttps:\/\/doi.org\/10.1002\/cncr.29154","journal-title":"Cancer"},{"issue":"5","key":"4791_CR19","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/1078-0432.CCR-13-2442","volume":"20","author":"XS Wang","year":"2014","unstructured":"Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS (2014) Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 20(5):1366\u20131374. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2442","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4791_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.bbi.2010.03.009","volume":"24","author":"XS Wang","year":"2010","unstructured":"Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z (2010) Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24(6):968\u2013974. \nhttps:\/\/doi.org\/10.1016\/j.bbi.2010.03.009","journal-title":"Brain Behav Immun"},{"issue":"5","key":"4791_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.bbi.2011.12.007","volume":"26","author":"XS Wang","year":"2012","unstructured":"Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS (2012) Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699\u2013705. \nhttps:\/\/doi.org\/10.1016\/j.bbi.2011.12.007","journal-title":"Brain Behav Immun"},{"issue":"1","key":"4791_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/SPC.0b013e32835dabe3","volume":"7","author":"LJ Wood","year":"2013","unstructured":"Wood LJ, Weymann K (2013) Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster. Curr Opin Support Palliat Care 7(1):54\u201359. \nhttps:\/\/doi.org\/10.1097\/SPC.0b013e32835dabe3","journal-title":"Curr Opin Support Palliat Care"},{"issue":"5","key":"4791_CR23","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jpainsymman.2018.01.008","volume":"55","author":"KL Kwekkeboom","year":"2018","unstructured":"Kwekkeboom KL, Tostrud L, Costanzo E, Coe CL, Serlin RC, Ward SE, Zhang Y (2018) The role of inflammation in the pain, fatigue, and sleep disturbance symptom cluster in advanced cancer. J Pain Symptom Manag 55(5):1286\u20131295. \nhttps:\/\/doi.org\/10.1016\/j.jpainsymman.2018.01.008","journal-title":"J Pain Symptom Manag"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04791-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04791-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04791-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:20:23Z","timestamp":1589628023000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04791-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["4791"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04791-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"11 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The MD Anderson Symptom Inventory is copyrighted and licensed by The University of Texas MD Anderson Cancer Center and Charles S. Cleeland. Xin Shelley Wang is the spouse of Charles S. Cleeland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Presented in part at the American Society for Clinical Oncology (ASCO) Annual Meeting; Chicago, Illinois, 06\/2014.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentation"}},{"value":"Supported in part by an Institutional Research Grant from The University of Texas MD Anderson Cancer Center and by grants from the National Cancer Institute of the National Institutes of Health: grants R01 CA026582 and P01 CA124787 (PI: Charles Cleeland); the Paul Calabresi Clinical Trial Program Subaward of NCI grant K12 CA088084 (PI: Robert Bast); and the MD Anderson Cancer Center Support (Core) Grant P30 CA016672 (PI: Peter Pisters).DisclaimerThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Grant or financial support"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}